Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study
Aim Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction‐associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment. Methods This multicenter observat...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2024-02, Vol.54 (2), p.201-212 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 212 |
|---|---|
| container_issue | 2 |
| container_start_page | 201 |
| container_title | Hepatology research |
| container_volume | 54 |
| creator | Fukunaga, Shuhei Mukasa, Michita Nakane, Tomoyuki Nakano, Dan Tsutsumi, Tsubasa Chou, Tomonori Tanaka, Hiroshi Hayashi, Daiki Minami, Shinpei Ohuchi, Akihiro Nagata, Tsutomu Takaki, Kota Takaki, Hiroshi Miyajima, Ichiro Nouno, Ryuichi Araki, Toshihiro Morita, Taku Torimura, Takuji Okabe, Yoshinobu Kawaguchi, Takumi |
| description | Aim
Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction‐associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment.
Methods
This multicenter observational cohort study enrolled consecutive patients newly diagnosed with ESCC after endoscopic treatment. Patients were classified into MAFLD or non‐MAFLD groups. The MAFLD group was further classified into non‐obese and obese MAFLD groups with a body mass index cutoff value of 25 kg/m2. The impact of MAFLD on the recurrence of ESCC was evaluated using a decision tree algorithm and random forest analysis.
Results
A total of 147 patients (average age 69 years; male : female, 127:20; observational period, 2.4 years) were enrolled. The 1‐, 3‐, and 5‐year recurrence rates were 2.0%, 21.1%, and 33.7%, respectively. Independent risk factors for the recurrence of ESCC were MAFLD (HR 2.2812; 95% confidence interval 1.0497–4.9571; p = 0.0373), drinking status, and smoking status. Metabolic dysfunction‐associated fatty liver disease was identified as the second most important classifier for recurrence, followed by drinking status. The cumulative incidence of ESCC recurrence was higher in the MAFLD group than in the non‐MAFLD group. In a subanalysis, the cumulative incidence of recurrence was significantly higher in the non‐obese than in the obese MAFLD group among abstainers/non‐drinkers. Directed acyclic graphs revealed that MAFLD directly contributes to ESCC recurrence.
Conclusions
MAFLD was independently and directly associated with ESCC recurrence after endoscopic treatment; a high recurrence rate was observed in patients with non‐obese MAFLD. Metabolic dysfunction‐associated fatty liver disease may identify patients at high risk for ESCC recurrence.
Metabolic dysfunction‐associated fatty liver disease (MAFLD), along with drinking and smoking, is an independent risk factor for the recurrence of esophageal squamous cell carcinoma after endoscopic treatment. Decision tree and random forest analyses revealed MAFLD as the second most important classifier for recurrence, followed by drinking. Acyclic graphs revealed that MAFLD directly contributes to the recurrence. Furthermore, the cumulative incidence of recurrence was significantly higher in the non‐obese than that in the obese MAFLD group among abstainers/non‐drinkers. |
| doi_str_mv | 10.1111/hepr.13973 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2873251654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2921278398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3573-90125b4f7f0da6a2be31be251dcc685f9a9a78d48b86261e883b0d523b1a03503</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEoj-w4QGQJTaoUop_EsdhV1WFVqoEQiCxixxnwnVJ7NRjU2XHI_B4rHkSfO8tLFjgjS3NN2fO-BTFM0ZPWT6vNrCEUybaRjwoDplqeElF9flhfgslSykqeVAcId5QyhrKq8fFgWiaVtaSHxY_r-ZFm0j8SJx3v77_8D0gkBmi7v1kDRlWHJMz0e6qGtEbqyMMZNQxrmSy3yCQwSLo3OYdCRa_5pqJPiAZfSBxAySASSGAM7AdBOiXjf4CeiJ4m_TsExID00SMDsY6P2sSA-yG3Nm4IeAGj8Yv2Q2mfk7GY27NMxF2vl6TMzKnKVoDLmY3GNOwPikejXpCeHp_Hxef3lx8PL8sr9-9vTo_uy6NqBtRtpTxuq_GZqSDlpr3IFgPvGaDMVLVY6tb3aihUr2SXDJQSvR0qLnomaaipuK4eLnXXYK_TYCxmy1ut9EO8mIdV43IcrKuMvriH_TGp-Cyu463nPFGiVZl6mRPmeARA4zdEuysw9ox2m3z7rZ5d7u8M_z8XjJ_DAx_0T8BZ4DtgTs7wfofqe7y4v2Hvehv7ka9yQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2921278398</pqid></control><display><type>article</type><title>Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Fukunaga, Shuhei ; Mukasa, Michita ; Nakane, Tomoyuki ; Nakano, Dan ; Tsutsumi, Tsubasa ; Chou, Tomonori ; Tanaka, Hiroshi ; Hayashi, Daiki ; Minami, Shinpei ; Ohuchi, Akihiro ; Nagata, Tsutomu ; Takaki, Kota ; Takaki, Hiroshi ; Miyajima, Ichiro ; Nouno, Ryuichi ; Araki, Toshihiro ; Morita, Taku ; Torimura, Takuji ; Okabe, Yoshinobu ; Kawaguchi, Takumi</creator><creatorcontrib>Fukunaga, Shuhei ; Mukasa, Michita ; Nakane, Tomoyuki ; Nakano, Dan ; Tsutsumi, Tsubasa ; Chou, Tomonori ; Tanaka, Hiroshi ; Hayashi, Daiki ; Minami, Shinpei ; Ohuchi, Akihiro ; Nagata, Tsutomu ; Takaki, Kota ; Takaki, Hiroshi ; Miyajima, Ichiro ; Nouno, Ryuichi ; Araki, Toshihiro ; Morita, Taku ; Torimura, Takuji ; Okabe, Yoshinobu ; Kawaguchi, Takumi</creatorcontrib><description>Aim
Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction‐associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment.
Methods
This multicenter observational cohort study enrolled consecutive patients newly diagnosed with ESCC after endoscopic treatment. Patients were classified into MAFLD or non‐MAFLD groups. The MAFLD group was further classified into non‐obese and obese MAFLD groups with a body mass index cutoff value of 25 kg/m2. The impact of MAFLD on the recurrence of ESCC was evaluated using a decision tree algorithm and random forest analysis.
Results
A total of 147 patients (average age 69 years; male : female, 127:20; observational period, 2.4 years) were enrolled. The 1‐, 3‐, and 5‐year recurrence rates were 2.0%, 21.1%, and 33.7%, respectively. Independent risk factors for the recurrence of ESCC were MAFLD (HR 2.2812; 95% confidence interval 1.0497–4.9571; p = 0.0373), drinking status, and smoking status. Metabolic dysfunction‐associated fatty liver disease was identified as the second most important classifier for recurrence, followed by drinking status. The cumulative incidence of ESCC recurrence was higher in the MAFLD group than in the non‐MAFLD group. In a subanalysis, the cumulative incidence of recurrence was significantly higher in the non‐obese than in the obese MAFLD group among abstainers/non‐drinkers. Directed acyclic graphs revealed that MAFLD directly contributes to ESCC recurrence.
Conclusions
MAFLD was independently and directly associated with ESCC recurrence after endoscopic treatment; a high recurrence rate was observed in patients with non‐obese MAFLD. Metabolic dysfunction‐associated fatty liver disease may identify patients at high risk for ESCC recurrence.
Metabolic dysfunction‐associated fatty liver disease (MAFLD), along with drinking and smoking, is an independent risk factor for the recurrence of esophageal squamous cell carcinoma after endoscopic treatment. Decision tree and random forest analyses revealed MAFLD as the second most important classifier for recurrence, followed by drinking. Acyclic graphs revealed that MAFLD directly contributes to the recurrence. Furthermore, the cumulative incidence of recurrence was significantly higher in the non‐obese than that in the obese MAFLD group among abstainers/non‐drinkers.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13973</identifier><identifier>PMID: 37796562</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Body mass index ; Endoscopy ; Esophageal cancer ; Esophageal carcinoma ; Fatty liver ; Liver diseases ; Metabolism ; non‐obese ; obesity ; overweight ; Risk factors ; Squamous cell carcinoma</subject><ispartof>Hepatology research, 2024-02, Vol.54 (2), p.201-212</ispartof><rights>2023 Japan Society of Hepatology.</rights><rights>2024 Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3573-90125b4f7f0da6a2be31be251dcc685f9a9a78d48b86261e883b0d523b1a03503</citedby><cites>FETCH-LOGICAL-c3573-90125b4f7f0da6a2be31be251dcc685f9a9a78d48b86261e883b0d523b1a03503</cites><orcidid>0000-0001-6571-9874 ; 0000-0002-7064-4325 ; 0000-0002-2715-7564</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13973$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13973$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37796562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fukunaga, Shuhei</creatorcontrib><creatorcontrib>Mukasa, Michita</creatorcontrib><creatorcontrib>Nakane, Tomoyuki</creatorcontrib><creatorcontrib>Nakano, Dan</creatorcontrib><creatorcontrib>Tsutsumi, Tsubasa</creatorcontrib><creatorcontrib>Chou, Tomonori</creatorcontrib><creatorcontrib>Tanaka, Hiroshi</creatorcontrib><creatorcontrib>Hayashi, Daiki</creatorcontrib><creatorcontrib>Minami, Shinpei</creatorcontrib><creatorcontrib>Ohuchi, Akihiro</creatorcontrib><creatorcontrib>Nagata, Tsutomu</creatorcontrib><creatorcontrib>Takaki, Kota</creatorcontrib><creatorcontrib>Takaki, Hiroshi</creatorcontrib><creatorcontrib>Miyajima, Ichiro</creatorcontrib><creatorcontrib>Nouno, Ryuichi</creatorcontrib><creatorcontrib>Araki, Toshihiro</creatorcontrib><creatorcontrib>Morita, Taku</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><creatorcontrib>Okabe, Yoshinobu</creatorcontrib><creatorcontrib>Kawaguchi, Takumi</creatorcontrib><title>Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction‐associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment.
Methods
This multicenter observational cohort study enrolled consecutive patients newly diagnosed with ESCC after endoscopic treatment. Patients were classified into MAFLD or non‐MAFLD groups. The MAFLD group was further classified into non‐obese and obese MAFLD groups with a body mass index cutoff value of 25 kg/m2. The impact of MAFLD on the recurrence of ESCC was evaluated using a decision tree algorithm and random forest analysis.
Results
A total of 147 patients (average age 69 years; male : female, 127:20; observational period, 2.4 years) were enrolled. The 1‐, 3‐, and 5‐year recurrence rates were 2.0%, 21.1%, and 33.7%, respectively. Independent risk factors for the recurrence of ESCC were MAFLD (HR 2.2812; 95% confidence interval 1.0497–4.9571; p = 0.0373), drinking status, and smoking status. Metabolic dysfunction‐associated fatty liver disease was identified as the second most important classifier for recurrence, followed by drinking status. The cumulative incidence of ESCC recurrence was higher in the MAFLD group than in the non‐MAFLD group. In a subanalysis, the cumulative incidence of recurrence was significantly higher in the non‐obese than in the obese MAFLD group among abstainers/non‐drinkers. Directed acyclic graphs revealed that MAFLD directly contributes to ESCC recurrence.
Conclusions
MAFLD was independently and directly associated with ESCC recurrence after endoscopic treatment; a high recurrence rate was observed in patients with non‐obese MAFLD. Metabolic dysfunction‐associated fatty liver disease may identify patients at high risk for ESCC recurrence.
Metabolic dysfunction‐associated fatty liver disease (MAFLD), along with drinking and smoking, is an independent risk factor for the recurrence of esophageal squamous cell carcinoma after endoscopic treatment. Decision tree and random forest analyses revealed MAFLD as the second most important classifier for recurrence, followed by drinking. Acyclic graphs revealed that MAFLD directly contributes to the recurrence. Furthermore, the cumulative incidence of recurrence was significantly higher in the non‐obese than that in the obese MAFLD group among abstainers/non‐drinkers.</description><subject>Body mass index</subject><subject>Endoscopy</subject><subject>Esophageal cancer</subject><subject>Esophageal carcinoma</subject><subject>Fatty liver</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>non‐obese</subject><subject>obesity</subject><subject>overweight</subject><subject>Risk factors</subject><subject>Squamous cell carcinoma</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhSMEoj-w4QGQJTaoUop_EsdhV1WFVqoEQiCxixxnwnVJ7NRjU2XHI_B4rHkSfO8tLFjgjS3NN2fO-BTFM0ZPWT6vNrCEUybaRjwoDplqeElF9flhfgslSykqeVAcId5QyhrKq8fFgWiaVtaSHxY_r-ZFm0j8SJx3v77_8D0gkBmi7v1kDRlWHJMz0e6qGtEbqyMMZNQxrmSy3yCQwSLo3OYdCRa_5pqJPiAZfSBxAySASSGAM7AdBOiXjf4CeiJ4m_TsExID00SMDsY6P2sSA-yG3Nm4IeAGj8Yv2Q2mfk7GY27NMxF2vl6TMzKnKVoDLmY3GNOwPikejXpCeHp_Hxef3lx8PL8sr9-9vTo_uy6NqBtRtpTxuq_GZqSDlpr3IFgPvGaDMVLVY6tb3aihUr2SXDJQSvR0qLnomaaipuK4eLnXXYK_TYCxmy1ut9EO8mIdV43IcrKuMvriH_TGp-Cyu463nPFGiVZl6mRPmeARA4zdEuysw9ox2m3z7rZ5d7u8M_z8XjJ_DAx_0T8BZ4DtgTs7wfofqe7y4v2Hvehv7ka9yQ</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Fukunaga, Shuhei</creator><creator>Mukasa, Michita</creator><creator>Nakane, Tomoyuki</creator><creator>Nakano, Dan</creator><creator>Tsutsumi, Tsubasa</creator><creator>Chou, Tomonori</creator><creator>Tanaka, Hiroshi</creator><creator>Hayashi, Daiki</creator><creator>Minami, Shinpei</creator><creator>Ohuchi, Akihiro</creator><creator>Nagata, Tsutomu</creator><creator>Takaki, Kota</creator><creator>Takaki, Hiroshi</creator><creator>Miyajima, Ichiro</creator><creator>Nouno, Ryuichi</creator><creator>Araki, Toshihiro</creator><creator>Morita, Taku</creator><creator>Torimura, Takuji</creator><creator>Okabe, Yoshinobu</creator><creator>Kawaguchi, Takumi</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6571-9874</orcidid><orcidid>https://orcid.org/0000-0002-7064-4325</orcidid><orcidid>https://orcid.org/0000-0002-2715-7564</orcidid></search><sort><creationdate>202402</creationdate><title>Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study</title><author>Fukunaga, Shuhei ; Mukasa, Michita ; Nakane, Tomoyuki ; Nakano, Dan ; Tsutsumi, Tsubasa ; Chou, Tomonori ; Tanaka, Hiroshi ; Hayashi, Daiki ; Minami, Shinpei ; Ohuchi, Akihiro ; Nagata, Tsutomu ; Takaki, Kota ; Takaki, Hiroshi ; Miyajima, Ichiro ; Nouno, Ryuichi ; Araki, Toshihiro ; Morita, Taku ; Torimura, Takuji ; Okabe, Yoshinobu ; Kawaguchi, Takumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3573-90125b4f7f0da6a2be31be251dcc685f9a9a78d48b86261e883b0d523b1a03503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body mass index</topic><topic>Endoscopy</topic><topic>Esophageal cancer</topic><topic>Esophageal carcinoma</topic><topic>Fatty liver</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>non‐obese</topic><topic>obesity</topic><topic>overweight</topic><topic>Risk factors</topic><topic>Squamous cell carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fukunaga, Shuhei</creatorcontrib><creatorcontrib>Mukasa, Michita</creatorcontrib><creatorcontrib>Nakane, Tomoyuki</creatorcontrib><creatorcontrib>Nakano, Dan</creatorcontrib><creatorcontrib>Tsutsumi, Tsubasa</creatorcontrib><creatorcontrib>Chou, Tomonori</creatorcontrib><creatorcontrib>Tanaka, Hiroshi</creatorcontrib><creatorcontrib>Hayashi, Daiki</creatorcontrib><creatorcontrib>Minami, Shinpei</creatorcontrib><creatorcontrib>Ohuchi, Akihiro</creatorcontrib><creatorcontrib>Nagata, Tsutomu</creatorcontrib><creatorcontrib>Takaki, Kota</creatorcontrib><creatorcontrib>Takaki, Hiroshi</creatorcontrib><creatorcontrib>Miyajima, Ichiro</creatorcontrib><creatorcontrib>Nouno, Ryuichi</creatorcontrib><creatorcontrib>Araki, Toshihiro</creatorcontrib><creatorcontrib>Morita, Taku</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><creatorcontrib>Okabe, Yoshinobu</creatorcontrib><creatorcontrib>Kawaguchi, Takumi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fukunaga, Shuhei</au><au>Mukasa, Michita</au><au>Nakane, Tomoyuki</au><au>Nakano, Dan</au><au>Tsutsumi, Tsubasa</au><au>Chou, Tomonori</au><au>Tanaka, Hiroshi</au><au>Hayashi, Daiki</au><au>Minami, Shinpei</au><au>Ohuchi, Akihiro</au><au>Nagata, Tsutomu</au><au>Takaki, Kota</au><au>Takaki, Hiroshi</au><au>Miyajima, Ichiro</au><au>Nouno, Ryuichi</au><au>Araki, Toshihiro</au><au>Morita, Taku</au><au>Torimura, Takuji</au><au>Okabe, Yoshinobu</au><au>Kawaguchi, Takumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2024-02</date><risdate>2024</risdate><volume>54</volume><issue>2</issue><spage>201</spage><epage>212</epage><pages>201-212</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction‐associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment.
Methods
This multicenter observational cohort study enrolled consecutive patients newly diagnosed with ESCC after endoscopic treatment. Patients were classified into MAFLD or non‐MAFLD groups. The MAFLD group was further classified into non‐obese and obese MAFLD groups with a body mass index cutoff value of 25 kg/m2. The impact of MAFLD on the recurrence of ESCC was evaluated using a decision tree algorithm and random forest analysis.
Results
A total of 147 patients (average age 69 years; male : female, 127:20; observational period, 2.4 years) were enrolled. The 1‐, 3‐, and 5‐year recurrence rates were 2.0%, 21.1%, and 33.7%, respectively. Independent risk factors for the recurrence of ESCC were MAFLD (HR 2.2812; 95% confidence interval 1.0497–4.9571; p = 0.0373), drinking status, and smoking status. Metabolic dysfunction‐associated fatty liver disease was identified as the second most important classifier for recurrence, followed by drinking status. The cumulative incidence of ESCC recurrence was higher in the MAFLD group than in the non‐MAFLD group. In a subanalysis, the cumulative incidence of recurrence was significantly higher in the non‐obese than in the obese MAFLD group among abstainers/non‐drinkers. Directed acyclic graphs revealed that MAFLD directly contributes to ESCC recurrence.
Conclusions
MAFLD was independently and directly associated with ESCC recurrence after endoscopic treatment; a high recurrence rate was observed in patients with non‐obese MAFLD. Metabolic dysfunction‐associated fatty liver disease may identify patients at high risk for ESCC recurrence.
Metabolic dysfunction‐associated fatty liver disease (MAFLD), along with drinking and smoking, is an independent risk factor for the recurrence of esophageal squamous cell carcinoma after endoscopic treatment. Decision tree and random forest analyses revealed MAFLD as the second most important classifier for recurrence, followed by drinking. Acyclic graphs revealed that MAFLD directly contributes to the recurrence. Furthermore, the cumulative incidence of recurrence was significantly higher in the non‐obese than that in the obese MAFLD group among abstainers/non‐drinkers.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37796562</pmid><doi>10.1111/hepr.13973</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6571-9874</orcidid><orcidid>https://orcid.org/0000-0002-7064-4325</orcidid><orcidid>https://orcid.org/0000-0002-2715-7564</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2024-02, Vol.54 (2), p.201-212 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2873251654 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Body mass index Endoscopy Esophageal cancer Esophageal carcinoma Fatty liver Liver diseases Metabolism non‐obese obesity overweight Risk factors Squamous cell carcinoma |
| title | Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A28%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20non%E2%80%90obese%20metabolic%20dysfunction%E2%80%90associated%20fatty%20liver%20disease%20on%20risk%20factors%20for%20the%20recurrence%20of%20esophageal%20squamous%20cell%20carcinoma%20treated%20with%20endoscopic%20submucosal%20dissection:%20A%20multicenter%20study&rft.jtitle=Hepatology%20research&rft.au=Fukunaga,%20Shuhei&rft.date=2024-02&rft.volume=54&rft.issue=2&rft.spage=201&rft.epage=212&rft.pages=201-212&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13973&rft_dat=%3Cproquest_cross%3E2921278398%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2921278398&rft_id=info:pmid/37796562&rfr_iscdi=true |